期刊
OLIGONUCLEOTIDES
卷 19, 期 3, 页码 209-222出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/oli.2009.0199
关键词
-
资金
- NCI NIH HHS [R01 CA138503] Funding Source: Medline
- NHLBI NIH HHS [T32 HL007344] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA138503] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER
Structured single-stranded nucleic acids, or aptamers, bind target molecules with high affinity and specificity, which translates into unique therapeutic possibilities. Currently, aptamers can be identified to most proteins, including blood-clotting factors, cell-surface receptors, and transcription factors. Chemical modifications to the oligonucleotides enhance their pharmacokinetics and pharmacodynamics, thus extending their therapeutic potential. Several aptamers have entered the clinical pipeline for applications and diseases such as macular degeneration, coronary artery bypass graft surgery, and various types of cancer. Furthermore, the functional repertoire of aptamers has expanded with the descriptions of multivalent agonistic aptamers and aptamers-siRNA chimeras. This review highlights those aptamers and aptamer-based approaches with particular likelihood of achieving therapeutic application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据